Engineered to target the cancer, not the patient
BiVictriX is building a novel pipeline of first-in-class therapeutics that have superior cancer selectivity. By significantly reducing harmful side-effects, we aim to vastly improve the safe dose of anti-cancer drugs patients can withstand, thus improving the overall effectiveness of treatment at eradicating the cancer.
Our approach relies on utilising our proprietary library of cancer-specific “twin antigen fingerprints”, which are uniquely expressed on the cancer; enabling them to be selectively targeted, while leaving healthy cells alone.
By applying this science, we created our Bi-Cygni® therapeutics.
We are unique in that we identify cancer-specific “fingerprints”, novel combinations of antigens which are co-expressed on the cancer cells but which are largely absent on healthy cells.
Coupled with this knowledge, we use our specialist know-how to design next-generation obligate bispecific therapeutics, capable of selectively targeting the cancer-specific “fingerprints” identified. Thereby fully exploiting the benefits of this promising approach.
The next phase in targeted cancer therapy
Significant benefits offered by Bi-Cygni® therapeutics
BIVICTRIX WHOLLY OWNED PIPELINE
SOLID TUMORS
BVX002
B7H4xTarget B
Bispecific ADC
Indications: Ovarian Cancer & Other Solid Tumors
Milestones: 2H 2026 – IND submission
BVX004
Undisclosed
Bispecific ADC
Indications: Multiple Solid Tumor
Bispecific
ADC Target Library
Indications: Multiple Tumor Indications
Target pair library identified across multiple solid tumor indication
HEMATOLOGICAL MALIGNANCIES
BVX001¹
CD7 x CD33
Bispecific ADC
Indications: Acute Myeloid Leukemia & Myelodysplastic Syndrome
Partnership Candidate
- Orphan drug designation granted in April 2024.
